Dyslipidemia

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The rates of ALT normalization maintained in both arms of the 96 week study.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.

Data from a phase 2 trial suggests evinacumab, in both subcutaneous and intravenous doses, were effective at lowering LDL-C in patients with refractory hypercholesterolemia.

Results of the RIVER trial suggest rivaroxaban was noninferior to warfarin for the study's composite endpoint of all-cause mortality, major cardiovascular events, and major bleeding.

In data presented at AAO 2020, researchers discover new methods for detecting different underlying conditions.

SimpleSENSE is a first-of-its-kind cloth-based diagnostic platform that can capture more than 100 million data points per patient per day across cardiac, pulmonary, and circulatory biomarkers.

Older patients benefit greater from LDL-cholesterol lowering medications.

Practical Cardiology's Chief Advisory Board member Dr. Guy Mintz and a principal investigator from the CLEAR program discuss bempedoic acid and how they envision it fitting into treatment algorithms going forward.

An analysis of more than 2k patients from hospitals in Spain detail associations between statin use and lower rates of COVID-19 mortality.

An analysis of data from patients presenting to a medical center in New York City details associations between statin use and mortality among diabetics hospitalized with COVID-19.

An analysis of the Dallas Heart Study from UTSW details how use of CAC scoring can help determine what patients would stand to benefit from aspirin use for primary prevention.